Key facts
- This page summarizes John Johnson's Form 4 filing for Axogen, Inc. (AXGN).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 10 Jun 2024, 18:20.
John Johnson - 06 Jun 2024 Form 4 Insider Report for Axogen, Inc. (AXGN)
- Reporting relationship
- Director
- Issuer ticker
- AXGN
- Reported as of
- 06 Jun 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 10 Jun 2024, 18:20:59 UTC
- Prior SEC filing
- 05 Jun 2024
- Next SEC filing
- 20 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ John Johnson
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
John Johnson filed Form 4 for Axogen, Inc. (AXGN) on 10 Jun 2024.
Change
- Previous filing in this sequence was filed on 05 Jun 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AXGN
transaction
Common Stock
Award
- Transaction value
- Shares
- +10,653
- Change %
- +165%
- Price
- Shares after
- 17,112
- Date
- 06 Jun 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AXGN
transaction
Derivative
Employee Stock Option (right to purchase)
Award
- Transaction value
- $0
- Shares
- +18,248
- Change %
- Price
- $0.000000
- Shares after
- 18,248
- Date
- 06 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 18,248
- Exercise price
- $7.04
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.
Footnote F2
Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 6, 2025, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.